Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

Business Leaders

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
HomeAll NewsMost read newsBusiness Leaders Biography
Portrait de Reshma Kewalramani
Age : 47
Public asset : 14,772,189 USD
Country of residence : Unknown
Linked companies : Vertex Pharmaceuticals Incorporated - Soaring Eagle Acquisition Corp.

Biography of Reshma Kewalramani 
Reshma Kewalramani is President, Chief Executive Officer & Director at Vertex Pharmaceuticals, Inc. In the past she was VP-Global Clinical Development & Nephrology at Amgen, Inc. She received a doctorate from Boston University School of Medicine.


Current positions of Reshma Kewalramani 
Holdings of Reshma Kewalramani 
Reshma Kewalramani : Personal Network 
Most Read News 
09/04BERNARD ARNAULT : There is no conflict with Arnault
RE
09/07GEORGE SOROS : Soros says BlackRock's China investments likely to lose money - WSJ
RE
09/14BRAD SMITH : Microsoft to buy back up to $60 billion in shares; names Brad Smith vice chair
RE
09/09FRANCESCO GAETANO CALTAGIRONE : Italy's Caltagirone ups Generali stake to just over 6%
RE
09/14CATHIE WOOD : ARK Invest's Wood expects market rotation back to growth stocks
RE
09/09ELON MUSK : Tesla's Musk asks staff to 'go super hardcore' to ensure decent Q3 delivery number
RE
09/13MARTIN SORRELL : Sorrell's S4 Capital raises annual profit outlook for a third time
RE
09/08ELON MUSK : Amazon.com goes for jugular in FCC spat with SpaceX's Musk
RE
09/08BILL GATES : Bill Gates' investment firm to take control of Four Seasons in $2.21 billion deal
RE
09/17STELIOS HAJI-IOANNOU : EasyJet shareholder Stelios Haji-Ioannou shuns rights issue -source
RE
More news


© 2021 People and Ownership :   
Reshma Kewalramani : Connections 


Latest news about Reshma Kewalramani 
06/09VERTEX PHARMA : FDA Approves Expanded Use of Trikaftato in Children
DJ
05/11Ginkgo Bioworks, Inc. entered into definitive agreement to acquire Soaring Eagle Acquisition Corp. from Eagle Equity Partners III, LLC and others for $16.7 billion in a reverse merger transaction.
CI
02/19INSIDER TRENDS : Insider at Vertex Pharmaceuticals Sells Stock for Taxes Interrupting 90-Day Buy Trend
MT
02/01VERTEX PHARMACEUTICALS' : 4Q Results Beat Expectations, Driven by Cystic Fibrosis Business -- Earnings Review
DJ
2020VERTEX PHARMACEUTICALS : Shares Plunge After Biotech Drops Closely Watched Drug Prospect
DJ
2020Vertex Pharmaceuticals Incorporated Announces Executive Changes
CI
2019Vertex Pharmaceuticals Incorporated Announces Executive Appointments
CI
More news